v3.26.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 1,303.9 $ 3,008.5
Current portion of marketable securities 0.0 807.2
Inventory 2,224.4 2,168.1
Other current assets 1,673.5 1,123.3
Total current assets 7,584.4 8,974.1
Marketable securities 0.0 431.9
Property, plant and equipment, net 2,967.6 3,055.4
Operating lease assets 176.1 265.4
Intangible assets, net 13,379.9 9,178.5
Goodwill 6,992.6 6,491.1
Deferred tax asset 293.7 292.5
Investments and other assets 659.8 750.6
Total assets 32,054.1 29,439.5
Current liabilities:    
Current portion of term loan 400.0 0.0
Taxes payable 54.5 114.8
Accounts payable 430.3 432.0
Accrued expense and other 3,013.6 2,802.6
Total current liabilities 3,898.4 3,349.4
Notes payable and term loan 7,292.0 6,286.8
Deferred tax liability 1,163.9 507.6
Long-term operating lease liabilities 109.3 290.4
Other long-term liabilities 668.4 748.5
Total liabilities 13,132.0 11,182.7
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 1,070.3 863.1
Accumulated other comprehensive income (loss) (120.3) (182.0)
Retained earnings 20,949.1 20,552.7
Treasury stock, at cost (2,977.1) (2,977.1)
Total equity 18,922.1 18,256.8
Total liabilities and equity 32,054.1 29,439.5
Nonrelated Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $3.1 and $3.0, respectively 1,884.6 1,342.4
Related Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $3.1 and $3.0, respectively $ 498.0 $ 524.6